Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.

about

Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.

Item

http://www.wikidata.org/entity/Q36234315

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Apatinib in gastric carcinoma: ...... treatment in advanced disease.

@ast

Apatinib in gastric carcinoma: ...... treatment in advanced disease.

@en

type

Item

label

Apatinib in gastric carcinoma: ...... treatment in advanced disease.

@ast

Apatinib in gastric carcinoma: ...... treatment in advanced disease.

@en

prefLabel

Apatinib in gastric carcinoma: ...... treatment in advanced disease.

@ast

Apatinib in gastric carcinoma: ...... treatment in advanced disease.

@en

P1476

Apatinib in gastric carcinoma: ...... treatment in advanced disease.

@en

P2093

Hairong Zhou

http://www.w3.org/2001/XMLSchema#string

Haoran Zhang

http://www.w3.org/2001/XMLSchema#string

Minghong Bi

http://www.w3.org/2001/XMLSchema#string

Shu Chang

http://www.w3.org/2001/XMLSchema#string

Yaping Wang

http://www.w3.org/2001/XMLSchema#string

Zhenyuan Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

HER2-positive gastric cancer.

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

P31

scholarly article

P356

10.1111/AJCO.12648

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28028915

http://www.w3.org/2001/XMLSchema#string